Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
34.21B
Cash
3.30B
Avg Qtr Burn
N/A
Short % of Float
1.98%
Insider Ownership
0.16%
Institutional Own.
60.12%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AUSTEDO® XR (deutetrabenazine) Details Huntington's disease, Dyskinesia | Approved Quarterly sales | |
SELARSDI™ (ustekinumab-aekn) Details Crohns disease, Ulcerative colitis | Approved Quarterly sales | |
UZEDY (risperidone) Details Schizophrenia, Mental health | Approved Quarterly sales | |
TVB-009P (denosumab) (Prolia Biosimilar) Details Osteoporosis | PDUFA Approval decision | |
TEV-’248 (ICS/SABA) Details Asthma | Phase 3 Data readout | |
Phase 3 Data readout | ||
AJOVY® (fremanezumab) Details Migraines | Phase 3 Data readout | |
Duvakitug / TEV-’574 (Anti-TL1A) Details Ulcerative colitis, Crohns disease | Phase 2b Update | |
Emrusolmin / TEV-’286 Details Multiple System Atrophy | Phase 2 Initiation | |
Phase 1 Data readout | ||
TEV-’408 (Anti-IL15) Details Celiac disease | Phase 1 Data readout |